Tonix Pharmaceuticals Presents Promising Single-Dose Mpox Vaccine Candidate
Tonix Pharmaceuticals revealed preclinical data for TNX-801, a single-dose mpox vaccine that demonstrates durable protection in animals, including immunocompromised subjects. The vaccine could potentially address global health emergency challenges related to mpox outbreaks.
Pharmaceutical company Tonix Pharmaceuticals has presented compelling preclinical data for its single-dose mpox vaccine candidate, TNX-801, at the World Vaccine Congress Washington 2025. The oral presentation highlighted significant findings that could have substantial implications for addressing mpox outbreaks globally.
The vaccine demonstrated remarkable efficacy in protecting animals, including immunocompromised subjects, against both mpox and rabbitpox. Notably, the vaccine provided durable protection lasting six months, a critical feature for potential widespread immunization efforts.
TNX-801 is a minimally replicative live-virus vaccine that aligns with the World Health Organization's preferred target profile. This alignment suggests the vaccine could be a valuable tool in managing current and future mpox outbreaks that have been declared global health emergencies.
The development represents a significant step in public health preparedness, offering a potential single-dose solution for mpox prevention. By providing protection across diverse subject groups and maintaining efficacy over an extended period, TNX-801 could represent a breakthrough in vaccine technology for infectious disease management.